Use of single-pill combination therapy in the evolving paradigm of hypertension management

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 12, 2009, Pages 1869-1874

  Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Blood pressure; Combination therapy; Hypertension; Single pill combination

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANTIHYPERTENSIVE AGENT; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; LOW DRUG DOSE; MONOTHERAPY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC;

EID: 68149179486     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902980210     Document Type: Review

References (41)

1. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-1252 (Pubitemid 37553153)
3. Joint National Committee. Report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. A cooperative study. JAMA 1977;237:255-261
4. The 1980 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1980;140:1280-1285
5. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-2446 (Pubitemid 27517978)
6. Mancia G, de Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension. Blood Press 2007;16:135-232
7. Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 2006;48:846-852
8. Ruzicka M, Leenen FH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001;61:943-954 (Pubitemid 32575395)
9. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031 (Pubitemid 38781102)
10. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-2051 (Pubitemid 38781107)
11. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428
12. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003;9:324-332
13. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-719 (Pubitemid 47176510)
14. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007;64:1279-1283 (Pubitemid 47216196)
15. Dusing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin 2006;22:1545-1553 (Pubitemid 44297433)
16. Ruilope LM, Burnier M, Muszbek N, et al. Public health value of fixed-dose combinations in hypertension. Blood Press Suppl 2008;1:5-14
17. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the council for high blood pressure research. Circulation 2008;117:e510-26
18. Basile JN. Fixed-dose combination therapy in the treatment of hypertension: ready for prime time. South Med J 2007;100:343-344 (Pubitemid 46559158)
19. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008;28:713-734
20. Hyzaar. losartan-hydrochlorothiazide Full Prescribing Information. Merck & Co, Inc.: Whitehouse Station, NJ 2008
21. Avalide (irbesartan/hydrochlorothiazide). Full Prescribing Information, Bristol-Myers Squibb Company, Princeton, NJ, 2007
22. Diovan HCT® (valsartan and hydrochlorothiazide). Full Prescribing Information, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2008
23. Exforge (valsartan/amlodipine). Full Prescribing Information, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2008
24. Daiichi Sankyo, Inc. files Supplemental New Drug Application for AZOR® as initial therapy for high blood pressure, 2008. Available from: http://www.sankyopharma.com/news/ pdfs/AZOR-sNDA-Initial-Therapy- Press-Release-FINAL091708.pdf [Last accessed 8 December 2008]
25. Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol 1995;35:1060-1066
26. Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004;17:495-501 (Pubitemid 38726163)
27. Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/ benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens 2002;15:550-556
28. Pool J, Kaihlanen P, Lewis G, et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001;15:495-498 (Pubitemid 32640266)
29. Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J Am Soc Hypertens 2008;2:294-302
30. Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2008 In press
31. Hasebe N, Kikuchi K. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005;23:445-453 (Pubitemid 40279649)
32. Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002;15:544-549 (Pubitemid 34596962)
33. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-580 (Pubitemid 47028551)
34. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427-1434
35. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American college of endocrinology and the American association of clinical endocrinologists. Endocr Pract 2008;14:933-946
36. Watts G. What happened to the polypill? BMJ 2008;337:a1822
37. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419
38. Yusuf S, Pais P, The Indian Polycap Study (TIPS) investigators. Impact of combinations of three blood pressure lowering drugs, a statin and aspirin on cardiovascular risk factors in 2000 individuals without cardiovascular disease American College of Cardiology; Orlando, FL; 2009
39. The Indian Polycap Study (TIPS) investigators. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomized trial. Lancet 2009;Early Online Publication, 30 March
40. Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich) 2007;9:19-24
41. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-930